Total Body Irradiation for Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia.
- Author:
Su Mi CHUNG
1
;
Ihl Bohng CHOI
;
Ki Mun KANG
;
In Ah KIM
;
Kyung Sub SHINN
;
Choon Choo KIM
;
Dong Jip KIM
Author Information
1. Department of Therapeutic Radiology, st. Mary's Hospital, Catholic University Medical College, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Chronic myelogenous leukemia;
Total body irradiation;
Allogeneic bone marrow transplantation
- MeSH:
Bone Marrow Transplantation*;
Bone Marrow*;
Cyclophosphamide;
Cyclosporine;
Daunorubicin;
Doxorubicin;
Graft vs Host Disease;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Leukemia, Myeloid;
Methotrexate;
Recurrence;
Siblings;
Splenectomy;
Tissue Donors;
Whole-Body Irradiation*
- From:Journal of the Korean Society for Therapeutic Radiology
1994;12(2):209-218
- CountryRepublic of Korea
- Language:English
-
Abstract:
Between July 1987 and December 1992, we treated 22 patients with chromic myelogenous leukemia; 14 in the chronic phase and 8 with more advanced disease. All were received with allogeneic bone marrow transplantation from HLA-identical sibling donors after a total body irradiation (TBI) cyclophosphamide conditioning regimen. Patients were non-randomly assigned to either 1200 cGy/6fractions/3days (6 patients) or 1320 cGy/8 fractions/4days (16 patients) by dose of TBI. Of the 22 patients, 8 were prepared with cyclophosphamide alone, 14 were conditioned with additional adriamycin or daunorubicin. To prevent graft versus host disease, cyclosporine was given either alone or in conjunction with methotrexate. The actuarial survival and leukemic-free survival at four years were 58.5% and 41.2%, respectively, and the relapse rate was 36% among 22 patients. There was a statistically significant difference in survival between the patients in chronic phase and more advanced phase (76% vs 33%, p=0.05). The relapse rate of patients receiving splenectomy was higher than that of patients receiving splenic irradiation (50% vs 0%, p=0.04). We conclude that the probability of cure is highest if transplantation is performed while the patient remains in the chronic phase.
